A Phase 1b, Single-Center, Double-Blind, Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 100 mg and 400 mg Oral Amphotericin B (iCo-019) or Placebo Administered for 10 Days in Healthy Subjects

iCo Therapeutics Inc0 个研究点目标入组 12 人开始时间: 2019年12月11日最近更新: 2020年1月6日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方: iCo Therapeutics Inc
入组人数: 12

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomised controlled trial
主要目的: Treatment
盲法: Blinded (masking used)

入排标准

年龄范围: 18 Years 至 55 Years（—）
性别: All

入选标准

•1. Healthy subjects as demonstrated by physical examination, medical history and overall assessment by the Investigator, in consultation with the medical monitor (if required)
•2. Adult male or female volunteers, aged 18-55 years inclusive
•3. BMI of 18.0 kg/m2 to 30.0 kg/m2
•4. Not taking any prescription medication (with the exception of hormonal contraceptives for women of child-bearing potential [WOCBP]) within 14 days prior to study drug administration until 10 days after dosing; no use of Over-the-counter (OTC) medication (including paracetamol), or herbal and dietary health products within 48 hours prior to study drug administration until 10 days after dosing. Coated paracetamol may be used at the discretion of the investigator (or delegate).
•5. Women who are postmenopausal for 1 year or more (post-menopausal is defined as documented amenorrhea for at least 1 year with an FSH >/= 40 mIU/ml if menses has occurred within 2 years); women who are surgically sterilized; WOCBP who are nonlactating and using a highly effective form of birth control during the course of the study and for 30 days after the treatment period (i.e. established use of oral, injected, or implanted hormonal methods of contraception in combination with a barrier method; placement of an intrauterine device (IUD) or intrauterine system (IUS) in combination with a barrier method; sterilized male partner (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate) in combination with a barrier method; true abstinence) and have a negative beta-HCG result (human chorionic gonadotropin in serum or urine) at screening and check-in at Day-1.
•6. Male subjects must agree to practice abstinence; be surgically sterilized; or use a medically acceptable method of contraception/birth control if they have a female partner of child-bearing potential, as well as having the female partner use an effective form of contraception, throughout the study duration and for 90 days after the study is completed. Male participants must refrain from sperm donation for the purposes of conception while enrolled in this study and for a period of 3 months (the approximate duration of spermatogenesis) following drug exposure
•7. Able to read and understand the Informed Consent Form
•8. Willing to participate in the study

排除标准

•1. Any medical condition or prior therapy that, in the opinion of the investigator and in consultation with the medical monitor (if required), would make the subject unsuitable for this study
•2. Inability to swallow capsules
•3. Pregnant or breastfeeding, or planning to conceive until at least 30 days after the administration of Investigational Product
•4. Surgery within the previous 3 months (except for minor cosmetic or dental procedures)
•5. Symptoms of a clinically significant illness (eg, gastrointestinal illness, infection such as influenza, upper respiratory tract infection) in the four weeks before the study drug dosing that, in the opinion of the Investigator, may influence the outcome of the study
•6. Average weekly alcohol intake that exceeds 21 units per week (males) or 14 units (females) per week, or are unwilling to stop alcohol consumption for 2 days prior to study drug dosing until 10 days after dosing (one unit is equivalent to a half-pint (285 mL) of beer or 1 (25 mL) measure of spirits or 1 glass (125 mL) of wine).
•7. Positive alcohol breathalyzer test at screening or check-in at Day-1
•8. Positive urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, cotinine) at screening or check-in at Day-1
•9. Use of more than 4 tobacco- or nicotine-containing products per month within 6 months prior to first study dose, or unwilling to refrain from the use of such products from Screening until completion of the final study visit;
•10. Lactose intolerance or other gastrointestinal disease that in the opinion of the Investigator and in consultation with the medical monitor (if required), may alter the amount and rate of drug absorption (e.g. diarrhea, IBS, Celiac disease)
•11. Any serious medical condition; e.g., kidney, liver or cardiac disease (outside standard range of results), asthma, diabetes, thyroid disease, angioedema, hypertension, bleeding disorder, malignancy, seizure, neutropenia, AIDS, etc.
•12. Any condition, occupational reason or other responsibility that, in the judgment of the Investigator, would jeopardize the safety or rights of a volunteer, or render the subject unable to comply with the protocol
•13. Participation in another clinical trial and/or treatment received with any investigational agent within one month before the initial dose of study medication
•14. Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule.

研究者

发起方

iCo Therapeutics Inc

相似试验

进行中（未招募）

1 期

A Phase IIb, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Artery, 24 hour Ambulatory Blood Pressure, Lipids, Lipoproteins and Markers Vascular Inflammation, Oxidation and CV risk in Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents - N/APatients with Coronary Heart Disease (CHD) or CHD Risk EquivalentsMedDRA version: 9.1Level: HLGTClassification code 10013317Term: Lipid metabolism disorders

EUCTR2007-003406-10-FRF.Hoffmann-La Roche Ltd.450

进行中（未招募）

不适用

EUCTR2007-003406-10-ATF.Hoffmann-La Roche Ltd.450

进行中（未招募）

不适用

A Phase IIB, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Artery, 24 hour Ambulatory Blood Pressure, Lipids, Lipoproteins and Markers Vascular Inflammation, Oxidation and CV risk in Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents - ND

EUCTR2007-003406-10-ITROCHE450

进行中（未招募）

不适用

A Phase IIB, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of dalcetrapib by Measuring Flow Mediated Dilatation in the Brachial Artery, 24 hour Ambulatory Blood Pressure, Lipids, Lipoproteins and Markers Vascular Inflammation, Oxidation and CV risk in Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents - dal-VESSEPatients with Coronary Heart Disease (CHD) or CHD Risk Equivalents.MedDRA version: 9.1Level: LLTClassification code 10007649Term: Cardiovascular disorder

EUCTR2007-003406-10-DEF. Hoffmann-La Roche Ltd.450

进行中（未招募）

1 期

A Phase 2, Single Blind, Single Center, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, when Administered to Healthy Infants 6-8 months oldThe Novartis Meningococcal B Recombinant +/- OMV Vaccine is intended for prevention of meningitidis and/or septicemia cause by Neisseria menigitidis serogroup B. The objective of the Novartis Meningococcal B Recombinant +/-OMV Vaccine is to identify vaccine candidates that are safe and that provide functional immune responses against heterologus meningococcal B strains.

EUCTR2006-005589-38-GBovartis Vaccines and Diagnostics S.r.l.60